Adrenoleukodystrophy Drugs Market Report 2026

Adrenoleukodystrophy Drugs Market Overview

• Adrenoleukodystrophy Drugs market size has reached to $0.69 billion in 2025 • Expected to grow to $1.13 billion in 2030 at a compound annual growth rate (CAGR) of 10.3% • Growth Driver: Growing Healthcare Expenditure Fueling The Growth Of The Market Due To Increasing Demand For Advanced Treatments And Therapies • Market Trend: Regulatory Approvals Pave The Way For Advancements In Adrenoleukodystrophy (ALD) Treatment Options • North America was the largest region in 2025.

What Is Covered Under Adrenoleukodystrophy Drugs Market?

Adrenoleukodystrophy (ALD) drugs are medications used to manage symptoms and slow the progression of adrenoleukodystrophy (ALD), a rare genetic disorder that affects the nervous system and adrenal glands. It is caused by mutations in the ABCD1 gene, leading to the accumulation of very long-chain fatty acids (VLCFAs) in the brain, adrenal glands, and spinal cord. The main drug classes of adrenoleukodystrophy drugs are dietary supplements, antioxidants, corticosteroids, and enzyme replacement therapy. Dietary supplements refer to products taken orally that contain essential nutrients, such as vitamins, minerals, amino acids, and fatty acids, which help support overall health and may aid in managing conditions such as adrenoleukodystrophy (ALD). These drugs are used for various indications such as childhood cerebral adrenoleukodystrophy (CCALD), Addison's disease, and adrenomyeloneuropathy (AMN), administered through various routes such as oral, injectable, and intravenous routes. It caters to various patient age groups, such as pediatric, adult, and geriatric age groups, and these are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and others.

What Is The Adrenoleukodystrophy Drugs Market Growth Forecast?

The adrenoleukodystrophy drugs market size is expected to see rapid growth in the next few years. It will grow to $1.13 billion in 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to advances in gene therapy development, increasing orphan drug incentives, expansion of newborn screening programs, rising investment in rare neurological disorders, improved access to specialized care. Major trends in the forecast period include growing focus on rare genetic disorder treatments, increasing use of symptom management therapies, expansion of pediatric and orphan drug programs, rising research into disease-modifying therapies, increased genetic screening and early diagnosis.

What Is The Driver Of The Adrenoleukodystrophy Drugs Market?

The growing healthcare expenditure is expected to propel the growth of the adrenoleukodystrophy drugs market going forward. Healthcare expenditure refers to the total financial resources spent on medical services, healthcare products, and related services by governments, private organizations, and individuals. Healthcare expenditures are rising because of the aging population and the growing prevalence of chronic diseases, which require long-term care and continuous management, leading to increasing demand for healthcare services and higher expenditures. Healthcare expenditure drives the demand for adrenoleukodystrophy (ALD) drugs by increasing investments in specialized treatments for rare diseases, leading to higher costs for research, development, and patient care. For instance, in December 2024, according to the Centers for Medicare And Medicaid Services (CMS), a US-based federal agency, national health expenditures (NHE) grew 7.5% in 2023, outpacing GDP growth. NHE is projected to grow at 5.6% annually from 2023 to 2032. Therefore, the growing healthcare expenditure is driving the growth of the adrenoleukodystrophy drugs market.

Key Players In The Global Adrenoleukodystrophy Drugs Market

Major companies operating in the adrenoleukodystrophy drugs market are Bluebird bio Inc., Minoryx Therapeutics S.L., SwanBio Therapeutics Inc., Voyager Therapeutics Inc., Prevail Therapeutics, Magenta Therapeutics Inc., Ashvattha Therapeutics, MedDay Pharmaceuticals SAS, Viking Therapeutics Inc., Neuraxpharm, Pfizer Inc., Sanofi S.A., Novartis AG, AstraZeneca plc, Teva Pharmaceuticals USA Inc., Mallinckrodt Pharmaceuticals plc, Dr. Reddy’s Laboratories Ltd., Nutricia, SOM Biotech, Autobahn Therapeutics Inc.

Global Adrenoleukodystrophy Drugs Market Trends and Insights

Major companies operating in the adrenoleukodystrophy (ALD) drugs market are focusing on obtaining regulatory approvals to expand their product offerings, such as Investigational new drug (IND) clearance to enable initiation of a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy. Investigational new drug (IND) clearance refers to the regulatory authorization granted by the U.S. Food and Drug Administration (FDA) that allows a company or sponsor to begin testing a new drug or therapy in human clinical trials. For instance, in May 2023, Minoryx Therapeutics S.L., a Spain-based biotechnology company, received FDA approval to initiate a Phase 3 clinical trial (CALYX) for its lead candidate, leriglitazone (MIN-102), in treating adult male patients with X-linked adrenoleukodystrophy (X-ALD) and cerebral adrenoleukodystrophy (cALD). This milestone marks a crucial advancement in developing a potential therapy for cALD, offering hope to patients with limited treatment options. The trial will evaluate the drug’s safety and efficacy in slowing or halting disease progression. Positive results could pave the way for commercialization, addressing a critical unmet medical need.

What Are Latest Mergers And Acquisitions In The Adrenoleukodystrophy Drugs Market?

In June 2025, bluebird bio, a US-based gene therapy company specializing in treatments for severe genetic diseases such as sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy, was acquired by funds managed by Carlyle and SK Capital for an undisclosed amount. Through this acquisition, the company aims to accelerate the development and commercialization of its gene therapies, expand patient access, and strengthen partnerships with treatment centers and payers. bluebird bio is a US-based biotechnology company focused on developing innovative gene therapies for rare and life-threatening genetic disorders.

What Defines the Adrenoleukodystrophy Drugs Market?

The adrenoleukodystrophy drugs market consists of sales of products including corticosteroids, Lorenzo's oil, hydrocortisone tablets, prednisone tablets, and adrenocortical hormone replacement therapy products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Adrenoleukodystrophy Drugs Market Report 2026?

The adrenoleukodystrophy drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the adrenoleukodystrophy drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.